Table 1.
Summary of the effects of cannabinoids on EAE mouse models of multiple sclerosis.
| Ligand (Route) | Concentration (Time of Administration in Days Post Disease Induction) | Species (Sex) | Effect | Reference |
|---|---|---|---|---|
| CBD (IP) | 20 mg/kg (9–25) | C57BL/6 (f) | ↑ | [56] |
| CBD (IP) | 5–10 mg/kg (0) | C57BL/6 (f) | ↑ | [57] |
| 10 mg/kg (0) | ||||
| 50 mg/kg (0) | ||||
| CBD (OG) | 75 mg/kg (1) | C57BL/6 (f) | ↑ | [58] |
| CBD (IP) | 5 mg/kg (19–21) | C57BL/6 (f) | ↑ | [59] |
| CBD (IP) | 5 mg/kg (11–13) | C57BL/6 (f) | ↑ | [60] |
| CBD:Δ9-THC (IV) | 5 mg/kg (210) | Biozzi ABH (m/f) | ↑ | [61] |
| 10 mg/kg (210) | ||||
| CBD:Δ9-THC (SC) | 10 mg/kg (11) | C57BL/6 (f) | ↑ | [62] |
| Δ9-THC (SC) | 20 mg/kg (11) | C57BL/6 (f) | ↑ | [62] |
| CBD (SC) | 20 mg/kg (11) | C57BL/6 (f) | — | [62] |
| CBD:Δ9-THC (SC) | 10 mg/kg (10–15) | C57BL/6 (f) | ↑ | [63] |
| CBD (SC) | 20 mg/kg (10–15) | C57BL/6 (f) | — | [63] |
| Δ9-THC (SC) | 20 mg/kg (10–15) | C57BL/6 (f) | ↑ | [63] |
| CBD:Δ9-THC (IP) | 10 mg/kg (10–15) | C57BL/6 (f) | ↑ | [64] |
| CBD:Δ9-THC oil extract (OG) | 215 mg/kg (6–18) | Lewis (f) | ↑ | [65] |
| CBD oil extract (OG) | 215 mg/kg (6–18) | Lewis (f) | — | [65] |
| Δ9-THC oil extract (OG) | 215 mg/kg (6–18) | Lewis (f) | — | [65] |
IP = intra peritoneal; OG = oral gavage; IV intravenous; SC = subcutaneous; f = female; m = male; ↑ = positive reduction in symptomatology and histological markers; — = no significant change in symptomatology and histological markers.